Astellas And Maxygen Ink Global Development Deal For Autoimmune Candidate MAXY-4
This article was originally published in PharmAsia News
Executive Summary
Maxygen's early-July decision to bear down on advancing its lead neutropenia compound and next-generation CTLA4-Ig drugs, letting Bayer take its hemophilia program, is paying off with Astellas, which signed a global deal that brings $10 million up front